Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin β4
Authors:
- 3 May 2010
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1194 (1) , 199-206
Abstract
Neurotrophic corneal defects are difficult to heal and all too often lead to scarring and vision loss. Medical management is often of limited success. We describe the results of nine patients (ages 37–84) with chronic nonhealing neurotrophic corneal epithelial defects who were treated with thymosin beta 4 (Tβ4) sterile eye drops for 28 or 49 days with a follow‐up period of 30 days. Those with geographic defects (six patients) showed dramatic healing without clinically significant neovascularization. Stromal thinning was observed in one patient. Three patients with punctate epithelial defects did not have a demonstrable change in their clinical findings. Reduced ocular irritation was reported by all patients soon after treatment initiation. Results from these compassionate use cases indicate that Tβ4 may provide a novel, topical approach to wound healing in chronic nonhealing neurotrophic corneal ulcers.Keywords
This publication has 16 references indexed in Scilit:
- Matrix metalloproteinase activity is necessary for thymosin beta 4 promotion of epithelial cell migrationJournal of Cellular Physiology, 2007
- Thymosin beta 4 suppression of corneal NFκB: A potential anti-inflammatory pathwayExperimental Eye Research, 2007
- Thymosin β: actin-sequestering protein moonlights to repair injured tissuesTrends in Molecular Medicine, 2005
- Thymosin-β4 Modulates Corneal Matrix Metalloproteinase Levels and Polymorphonuclear Cell Infiltration after Alkali InjuryInvestigative Ophthalmology & Visual Science, 2005
- Thymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation in Vivo Following Alkali InjuryExperimental Eye Research, 2002
- Thymosin Beta 4 Promotes Corneal Wound Healing and Modulates Inflammatory Mediators in vivoExperimental Eye Research, 2001
- Thymosin β 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoidsNature Medicine, 1999
- Management of neurotrophic keratopathyCurrent Opinion in Ophthalmology, 1999
- Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic UlcersNew England Journal of Medicine, 1998
- Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets.Proceedings of the National Academy of Sciences, 1990